Eva Hellstrom-Lindberg

Summary

Affiliation: Karolinska Institutet
Country: Sweden

Publications

  1. doi request reprint Erythropoiesis stimulating agents and other growth factors in low-risk MDS
    Eva Hellstrom-Lindberg
    Department of Medicine, Division of Hematology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden Electronic address
    Best Pract Res Clin Haematol 26:401-10. 2013
  2. ncbi request reprint Supportive care, growth factors, and new therapies in myelodysplastic syndromes
    Eva Hellstrom-Lindberg
    Karolinska Institutet, Department of Medicine, Division of Hematology, Karolinska University Hospital Huddinge, 141 86 Stockholm, Sweden
    Blood Rev 22:75-91. 2008
  3. doi request reprint Significance of JAK2 and TET2 mutations in myelodysplastic syndromes
    Eva Hellstrom-Lindberg
    Karolinska Institutet, Department of Medicine, Division of Hematology, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Blood Rev 24:83-90. 2010
  4. doi request reprint Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes
    Eva Hellstrom-Lindberg
    Karolinska Institutet, Department of Medicine, Division of Hematology, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Semin Hematol 45:14-22. 2008
  5. doi request reprint TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression
    Martin Jadersten
    Center for Experimental Hematology M54, Karolinska Institutet, Karolinska University Hospital Huddinge, SE 141 86 Stockholm, Sweden
    J Clin Oncol 29:1971-9. 2011
  6. ncbi request reprint Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy
    Michael Grövdal
    Division of Haematology, Department of Medicine, Centre for Experimental Haematology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Br J Haematol 150:293-302. 2010
  7. ncbi request reprint Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes
    Ramin Tehranchi
    Department of Medicine, Division of Hematology, Karolinska Institutet, Karolinska University Hospital Huddinge, S 141 86 Stockholm, Sweden
    Blood 106:247-53. 2005
  8. doi request reprint Gene expression profiling of erythroblasts from refractory anaemia with ring sideroblasts (RARS) and effects of G-CSF
    Maryam Nikpour
    Centre of Experimental Haematology, Department of Medicine Huddinge, Karolinska Institute, Stockholm, Sweden
    Br J Haematol 149:844-54. 2010
  9. ncbi request reprint Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors
    Ramin Tehranchi
    Department of Medicine, Division of Hematology, Huddinge University Hospital, Stockholm, Sweden
    Blood 101:1080-6. 2003
  10. ncbi request reprint Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF
    Martin Jadersten
    Dept of Hematology, Karolinska University Hospital, Huddinge, 141 86 Stockholm, Sweden
    Blood 106:803-11. 2005

Detail Information

Publications29

  1. doi request reprint Erythropoiesis stimulating agents and other growth factors in low-risk MDS
    Eva Hellstrom-Lindberg
    Department of Medicine, Division of Hematology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden Electronic address
    Best Pract Res Clin Haematol 26:401-10. 2013
    ..Moreover, responding patients show improvement of quality of life and exercise capacity. Response to treatment can be predicted by combining serum erythropoietin, transfusion rate, and flow cytometry profiling. ..
  2. ncbi request reprint Supportive care, growth factors, and new therapies in myelodysplastic syndromes
    Eva Hellstrom-Lindberg
    Karolinska Institutet, Department of Medicine, Division of Hematology, Karolinska University Hospital Huddinge, 141 86 Stockholm, Sweden
    Blood Rev 22:75-91. 2008
    ..The role of these, alone and in combination with more established therapies will be discussed...
  3. doi request reprint Significance of JAK2 and TET2 mutations in myelodysplastic syndromes
    Eva Hellstrom-Lindberg
    Karolinska Institutet, Department of Medicine, Division of Hematology, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Blood Rev 24:83-90. 2010
    ....
  4. doi request reprint Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes
    Eva Hellstrom-Lindberg
    Karolinska Institutet, Department of Medicine, Division of Hematology, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Semin Hematol 45:14-22. 2008
    ..Severe thrombocytopenia has recently been reported to respond to thrombopoietic agents, such as AMG 531...
  5. doi request reprint TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression
    Martin Jadersten
    Center for Experimental Hematology M54, Karolinska Institutet, Karolinska University Hospital Huddinge, SE 141 86 Stockholm, Sweden
    J Clin Oncol 29:1971-9. 2011
    ..To determine the frequency of TP53 mutations and the level of p53 protein expression by immunohistochemistry (IHC) in low-risk myelodysplastic syndromes (MDS) with del(5q) and to assess their impact on disease progression...
  6. ncbi request reprint Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy
    Michael Grövdal
    Division of Haematology, Department of Medicine, Centre for Experimental Haematology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Br J Haematol 150:293-302. 2010
    ..5 and 30% of the cycles, respectively, while haemoglobin levels increased during treatment. 5-azacytidine treatment is safe, feasible and may be of benefit in a subset of patients...
  7. ncbi request reprint Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes
    Ramin Tehranchi
    Department of Medicine, Division of Hematology, Karolinska Institutet, Karolinska University Hospital Huddinge, S 141 86 Stockholm, Sweden
    Blood 106:247-53. 2005
    ..In conclusion, aberrant MtF expression in RARS erythroblasts occurs at a very early stage of erythroid differentiation and is paralleled by an up-regulation of genes involved in this process...
  8. doi request reprint Gene expression profiling of erythroblasts from refractory anaemia with ring sideroblasts (RARS) and effects of G-CSF
    Maryam Nikpour
    Centre of Experimental Haematology, Department of Medicine Huddinge, Karolinska Institute, Stockholm, Sweden
    Br J Haematol 149:844-54. 2010
    ..By contrast, G-CSF had no effect on iron-transport or erythropoiesis-associated genes...
  9. ncbi request reprint Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors
    Ramin Tehranchi
    Department of Medicine, Division of Hematology, Huddinge University Hospital, Stockholm, Sweden
    Blood 101:1080-6. 2003
    ....
  10. ncbi request reprint Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF
    Martin Jadersten
    Dept of Hematology, Karolinska University Hospital, Huddinge, 141 86 Stockholm, Sweden
    Blood 106:803-11. 2005
    ..Patients with high/intermediate probability of response and with IPSS Low/Int-1 show frequent and durable responses without adverse effects on outcome, while other patients should not be considered candidates for this treatment...
  11. ncbi request reprint Hypochromic red blood cells in low-risk myelodysplastic syndromes: effects of treatment with hemopoietic growth factors
    Therese Ljung
    Department of Medicine, Division of Hematology, Karolinska Institutet at Huddinge University Hospital, Stockholm, Sweden
    Haematologica 89:1446-53. 2004
    ..The present study was designed to assess whether functional iron deficiency may develop in MDS patients receiving these treatments...
  12. doi request reprint Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions
    Herman Nilsson-Ehle
    Section of Hematology and Coagulation, Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden
    Eur J Haematol 87:244-52. 2011
    ..The objective for this prospective phase II Nordic multicentre trial was to assess QoL, response rate and physical function in elderly anaemic MDS patients treated to a target Hb level of >120 g/L...
  13. pmc Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression
    Martin Jadersten
    Karolinska Institutet, Department of Medicine, Center for Experimental Hematology, Karolinska University Hospital, Stockholm, Sweden
    Haematologica 94:1762-6. 2009
    ....
  14. ncbi request reprint A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life
    Eva Hellstrom-Lindberg
    Department of Medicine, Karolinska Institutet at Huddinge University Hospital, Stockholm, Sweden
    Br J Haematol 120:1037-46. 2003
    ..01). The validated decision model defined a subgroup of patients with a response rate of 61% (95% confidence interval 48-74%) to treatment with G-CSF + Epo. The majority of these patients have shown complete and durable responses...
  15. ncbi request reprint Antiapoptotic role of growth factors in the myelodysplastic syndromes: concordance between in vitro and in vivo observations
    Ramin Tehranchi
    Department of Medicine, Division of Hematology, Karolinska University Hospital, Karolinska Institutet, Huddinge, Stockholm, Sweden
    Clin Cancer Res 11:6291-9. 2005
    ....
  16. ncbi request reprint Kostmann syndrome: severe congenital neutropenia associated with defective expression of Bcl-2, constitutive mitochondrial release of cytochrome c, and excessive apoptosis of myeloid progenitor cells
    Goran Carlsson
    Childhood Cancer Research Center, Department of Woman and Child Health, Karolinska Hospital, Stockholm, Sweden
    Blood 103:3355-61. 2004
    ..In sum, these studies establish a role for mitochondria-dependent apoptosis in the pathogenesis of Kostmann syndrome and yield a tentative explanation for the beneficial effect of growth factor administration in these patients...
  17. ncbi request reprint A pharmacodynamic study of 5-azacytidine in the P39 cell line
    Rasheed Khan
    Department of Medicine, Division of Hematology, Karolinska University Hospital Huddinge, Karolinska Institute, Stockholm, Sweden
    Exp Hematol 34:35-43. 2006
    ..The present in vitro study aimed at evaluating the pharmacodynamics of azacytidine, thereby providing a rationale for clinical dose-finding studies...
  18. doi request reprint Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes
    Andrea Pellagatti
    Andrea Pellagatti, Janet Perry, James S Wainscoat, and Jacqueline Boultwood, University of Oxford, Oxford Ken I Mills, Queen s University Belfast, Belfast Emma Jane McDonald and Sally Killick, Royal Bournemouth Hospital, Bournemouth, United Kingdom Axel Benner, German Cancer Research Center, Heidelberg Aristoteles Giagounidis, St Johannes Hospital, Duisburg Lars Bullinger, University Hospital of Ulm, Ulm, Germany Mario Cazzola, Luca Malcovati, and Matteo G Della Porta, Fondazione Istituto di Ricovera e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy Martin Jädersten and Eva Hellström Lindberg, Karolinska Institutet, Stockholm, Sweden and Amit Verma, Albert Einstein College of Medicine, New York, NY
    J Clin Oncol 31:3557-64. 2013
    ....
  19. doi request reprint Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome
    Martin Jadersten
    Karolinska Institutet, Department of Medicine, Division of Hematology, Stockholm, Sweden
    J Clin Oncol 26:3607-13. 2008
    ..To assess the effect of erythropoietin (EPO) plus granulocyte-colony stimulating factor (G-CSF) treatment on survival and leukemic transformation in myelodysplastic syndrome (MDS)...
  20. ncbi request reprint Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes
    Lars Göran Lundberg
    Department of Medicine, Stockholm Soder Hospital, The Karolinska Institutet, SE 141 86 Stockholm, Sweden
    Leuk Res 30:247-53. 2006
    ..Thus, our data do not support an important prognostic role of angiogenesis, reflected by microvessel density, in the myelodysplastic syndromes...
  21. doi request reprint Bone marrow dendritic cells are reduced in patients with high-risk myelodysplastic syndromes
    Leonie Saft
    Department of Pathology, Division of Hematopathology, Karolinska University Hospital and Institute, Stockholm, Sweden
    Leuk Res 37:266-73. 2013
    ..DC levels were markedly reduced in all subtypes of MDS. The clinical impact of this finding on therapy response and relapse after, e.g. allogeneic stem cell transplantation warrants further investigation...
  22. pmc p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)
    Leonie Saft
    Department of Medicine, Karolinska Institute, Karolinska University Hospital Huddinge, Sweden Department of Pathology, Karolinska University Hospital, Stockholm, Sweden
    Haematologica 99:1041-9. 2014
    ..This study was based on data from the MDS 004 trial (clinicaltrials.gov identifier: NCT00179621)...
  23. ncbi request reprint Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome
    Michael Grövdal
    Division of Haematology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Denmark
    Clin Cancer Res 13:7107-12. 2007
    ..This study was designed to assess the effect of methylation status on the outcome of conventional induction chemotherapy...
  24. ncbi request reprint Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes
    Per Anders Broliden
    Karolinska Institutet, Department of Medicine, Karolinska University, Hospital Huddinge, Stockholm, Sweden
    Haematologica 91:667-70. 2006
    ..Four out of 20 patients progressed to acute myeloid leukemia within a year. We conclude that immunosuppressive treatment may be a therapeutic option for selected patients with myelodysplastic syndrome...
  25. ncbi request reprint Approach to anemia associated with myelodysplastic syndromes
    Eva Hellstrom-Lindberg
    Karolinska Institutet, Department of Medicine, Division of Hematology at Huddinge University Hospital, 141 86 Stockholm, Sweden
    Curr Hematol Rep 2:122-9. 2003
    ..Such studies may lead to individually tailored therapy for MDS patients based on a detailed analysis of the role of different contributing mechanisms to the origins of their disease...
  26. doi request reprint New clues to the molecular pathogenesis of myelodysplastic syndromes
    Martin Jadersten
    Center for Experimental Hematology, Department of Medicine, Karolinska Institutet at Karolinska University Hospital, Stockholm, Sweden
    Exp Cell Res 316:1390-6. 2010
    ..An improved understanding of the pathophysiology of MDS may lead to the identification of suitable targets for future drug development...
  27. doi request reprint Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells
    Rasheed Khan
    Department of Medicine, Division of Hematology, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden
    Exp Hematol 36:149-57. 2008
    ..The present study aimed at characterizing the mechanisms for 5-azacytidine-induced apoptosis, as well as the presence of a possible link between apoptosis and DNA hypomethylation...
  28. ncbi request reprint Sixth International Symposium on Myelodysplastic Syndromes, Stockholm, June 14-17, 2001
    Eva Hellstrom-Lindberg
    Karolinska Institutet, Dept of Medicine, Huddinge University Hospital, Stockholm, Sweden
    Int J Hematol 75:209-12. 2002
  29. ncbi request reprint Lead poisoning from souvenir earthenware
    Eva Hellstrom-Lindberg
    Karolinska Institutet, Department of Medicine, Division of Hematology, Karolinska University Hospital, Huddinge, 141 86, Stockholm, Sweden
    Int Arch Occup Environ Health 79:165-8. 2006
    ..The intoxicated patient was successfully treated with dimercaptosuccinic acid. Ceramic producers should adhere to the longstanding European legislation...